Close Menu

NEW YORK (GenomeWeb) – Biodesix said today that it has acquired Seattle-based Integrated Diagnostics.

Financial terms of the deal were not disclosed.

The acquisition adds Indi's XL2 lung cancer test to Biodesix's portfolio. A second generation technology of what was previously called Xpresys Lung, the XL2 test measures two protein markers in the blood, which, combined with other pathologic and clinical factors, can improve the identification of cancers in individuals who have had a lung nodule detected via imaging.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Three genetic testing companies form a coalition to influence how Congress considers genetic privacy, The Hill reports.

University of California, San Diego researchers investigate how skin care products influence the skin microbiome, Scientific American reports.

The Wall Street Journal examines billing codes used by uBiome.

In PNAS this week: links between lung adenocarcinoma and lncRNA, algorithm to impute and cluster Hi-C interaction profiles from single cells, and more.